Getinge announces today the acquisition of 100% of the shares of Quadralene. Quadralene is a global manufacturer of, and expert in, decontamination products such as detergents and disinfectants for the health care and dental sector. Quadralene has annual net sales of approximately SEK 75 M and will be a part of Infection Control in the business area of Surgical Workflows.
“With the acquisition of Quadralene, we will bring additional value and support to our customers in their mission to reduce hospital-acquired infections,” says Stéphane Le Roy, President Surgical Workflows at Getinge. “Quadralene has a great reputation in the field of decontamination, and we are excited that they join Getinge as the future cornerstone of our newly created Center of Excellence dedicated to chemistry and instrument disinfection. In addition, we continue to execute on our strategic ambition to widen our Infection Control portfolio towards consumables, developed and manufactured internally, which will make our financial performance more robust and sustainable.”
Quadralene is a UK based company founded in 1930 which designs, commercializes, manufactures and delivers decontamination products globally. Approximately 75% of its revenue comes from the health care and dental sector and Getinge is today its largest customer with 43% of Quadralene’s revenue. The value of the global decontamination consumables, whereof mainly detergents, for Central Sterile Supply is estimated to be SEK 4,8B with an expected growth rate of 5% per year. Quadralene has its head office in Derby, UK and employs approximately 30 employees.
“In supporting Getinge to realize its strategic ambition, Quadralene is rightly being recognized for its expertise in decontamination technology,” says Bob Newsome, Managing Director Quadralene. “Our aim is to continue to innovate within our market, which has been the hallmark of our growth to date, and by becoming an in-house consumables manufacturer we hope to expand the global appeal of the whole Getinge portfolio. The creation of the Centre of Excellence for chemistry and instrument decontamination at our Derby offices is an important part for our business, and excellent news for the team at Quadralene and the city itself.”
Getinge acquires 100% of the shares of Quadralene for SEK 196 M (£17M) in cash with a potential earn-out up to SEK 27 M (£2,3M). Getinge expects no material integration costs in 2020-2021. The Quadralene acquisition is not expected to have a material impact on Getinge’s operating profit and earnings per share as of 2020.
For more information about Quadralene: www.quadralene.com.
Lars Mattson, Head of Investor Relations
Tel: +46 (0)10 335 0043
Anna Appelqvist, Vice President Corporate Communications
Tel: +46 (0)10 335 5906
With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs over 10,000 people worldwide and the products are sold in more than 135 countries.